Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
Conditions:   Anatomic Stage III Breast Cancer AJCC v8;   Anatomic Stage IIIA Breast Cancer AJCC v8;   Anatomic Stage IIIB Breast Cancer AJCC v8;   Anatomic Stage IIIC Breast Cancer AJCC v8;   Anatomic Stage IV Breast Cancer AJCC v8;   BRCA-Mutated Malignant Neoplasm;   BRCA-Mutated Metastatic Breast Carcinoma;   BRCA-Mutated Ovarian Carcinoma;   Metastatic Breast Carcinoma;   Metastatic Fallopian Tube Carcinoma;   Metastatic Malignant Solid Neoplasm;   Metastatic Ovarian Carcinoma;   Metastatic Pancreatic Carcinoma;   Metastatic Primary Peritoneal Carcinoma;   Prognostic Stage III Breast Cancer AJCC v8;   Prognostic Stage IIIA Breast Cancer AJCC v8;   Prognostic Stage IIIB Breast Cancer AJCC v8;   Prognostic Stage IIIC Breast Cancer AJCC v8;   Prognostic Stage IV Breast Cancer AJCC v8;   Stage III Fallopian Tube Cancer AJCC v8;   Stage III Ovarian Cancer AJCC v8;   Stage III Pancreatic Cancer AJCC v8;   Stage III Primary Peritoneal Cancer AJCC v8;   Stage IIIA Fallopian Tube Cancer AJCC v8;   Stage IIIA Ovarian Cancer AJCC v8;   Stage IIIA Primary Peritoneal Cancer AJCC v8;   Stage IIIA1 Fallopian Tube Cancer AJCC v8;   Stage IIIA1 Ovarian Cancer AJCC v8;   Stage IIIA2 Fallopian Tube Cancer AJCC v8;   Stage IIIA2 Ovarian Cancer AJCC v8;   Stage IIIB Fallopian Tube Cancer AJCC v8;   Stage IIIB Ovarian Cancer AJCC v8;   Stage IIIB Primary Peritoneal Cancer AJCC v8;   Stage IIIC Fallopian Tube Cancer AJCC v8;   Stage IIIC Ovarian Cancer AJCC v8;   Stage IIIC Primary Peritoneal Cancer AJCC v8;   Stage IV Fallopian Tube Cancer AJCC v8;   Stage IV Ovarian Cancer AJCC v8;   Stage IV Pancreatic Cancer AJCC v8;   Stage IV Primary Peritoneal Cancer AJCC v8;   Stage IVA Fallopian Tube Cancer AJCC v8;   Stage IVA Ovarian Cancer AJCC v8;   Stage IVA Primary Peritoneal Cancer AJCC v8;   Stage IVB Fallopian Tube Cancer AJCC v8;   Stage IVB Ovarian Cancer AJCC v8;   Stage IVB Primary Peritoneal Cancer AJCC v8;   Unresectable Breast Carcinoma;   Unresectable Fallopian Tube Carcinoma;   Unresectable Malignant Solid Neoplasm;   Unresectable Ovarian Carcinoma;   Unresectable Pancreatic Carcinoma;   Unresectable Primary Peritoneal Carcinoma
Interventions:   Biological: Dostarlimab;   Drug: Niraparib
Sponsors:   University of Washington;   GlaxoSmithKline

Source: View full study details on

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

September 29, 2022Comments | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine